Current and Future Management Strategies for Relapsed or Progressive Hepatoblastoma
- 1 August 2012
- journal article
- review article
- Published by Springer Nature in Pediatric Drugs
- Vol. 14 (4) , 221-232
Abstract
Hepatoblastoma is the most common primary malignant neoplasm of the liver in children. Improvements in chemotherapy and surgical techniques have increased survival rates for those with localized disease. The prognosis for patients with progressive or relapsed disease continues to be dismal. Complete resection by surgery or liver transplantation is necessary for cure. Few conventional chemotherapy agents have demonstrated activity in progressive or relapsed hepatoblastoma. Irinotecan has shown activity in relapsed and progressive hepatoblastoma. The efficacy of high-dose chemotherapy in this setting is unknown. Newer targeted agents that ‘selectively’ interfere with pathway targets involved in tumor growth and progression such as insulin-like growth factor, phosphatidylinositol 3-kinase (PI3K), Akt, and mammalian target of rapamycin (mTOR) are currently under development. Because of the rarity of hepatoblastoma, only a small minority of these agents will ever be evaluated in children with this disorder. Gene-directed therapy and immunotherapy have shown promising results in the preclinical setting, and should be investigated as future treatment options for advanced hepatoblastoma.Keywords
This publication has 134 references indexed in Scilit:
- Pushing the Envelope in the mTOR Pathway: The Second Generation of InhibitorsMolecular Cancer Therapeutics, 2011
- Sunitinib and other targeted therapies for renal cell carcinomaBritish Journal of Cancer, 2011
- Insulin-like growth factors and insulin control a multifunctional signalling network of significant importance in cancerBritish Journal of Cancer, 2010
- Defining the pathway to insulin-like growth factor system targeting in cancerBiochemical Pharmacology, 2010
- Cytotoxicity of Activated Natural Killer Cells against Pediatric Solid TumorsClinical Cancer Research, 2010
- Therapy‐induced antitumor vaccination in neuroblastomas by the combined targeting of IL‐2 and TNFαInternational Journal of Cancer, 2010
- PARP inhibition: PARP1 and beyondNature Reviews Cancer, 2010
- Activation of the hedgehog-signaling pathway in human cancer and the clinical implicationsOncogene, 2009
- Gene expression profiling reveals signatures characterizing histologic subtypes of hepatoblastoma and global deregulation in cell growth and survival pathwaysHuman Pathology, 2009
- Loss of imprinting of IGF2 correlates with hypermethylation of the H19 differentially methylated region in hepatoblastomaBritish Journal of Cancer, 2008